hero section gradient
12 handpicked stocks

Copy a $11.55Trn Asset Manager

Want to invest like the pros? This collection features stocks that BlackRock, the world's largest asset manager, has in their portfolio. These carefully selected investments represent the strategy of financial experts who manage trillions in assets.

Author avatar

Han Tan | Market Analyst

Published on May 21

Your Basket's Financial Footprint

Processed market capitalisation data for a stock basket, highlighting total market cap and investor key takeaways.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and closer correlation with broad-market performance, reducing idiosyncratic risk.
  • Suitable as a core, long-term holding within a diversified portfolio rather than a short-term speculative position.
  • Expect steady, long-term value accumulation rather than explosive short-term gains; growth likely moderate and gradual.
Total Market Cap
  • AAPL: $3.90T

  • MSFT: $3.85T

  • NVDA: $4.40T

  • Other

About This Group of Stocks

1

Our Expert Thinking

BlackRock manages over $11.55 trillion in assets with a proven strategy focused on diversification, long-term growth, and thorough market research. This collection lets you mirror their approach by investing in stocks they've selected after careful analysis.

2

What You Need to Know

These stocks reflect BlackRock's emphasis on diversification across sectors and company sizes. Their strategy typically balances risk through careful selection, focusing on long-term potential rather than short-term market fluctuations.

3

Why These Stocks

Each stock in this collection represents BlackRock's professional judgment based on extensive market research and analysis. These companies have been selected by one of the world's most respected financial institutions with a track record of successful asset management.

Why You'll Want to Watch These Stocks

🏆

Professional-Grade Picks

These aren't just any stocks - they're backed by BlackRock's $11.55 trillion expertise and rigorous analysis. You're getting access to the same investments chosen by the world's largest asset manager.

🔍

Backed By Serious Research

BlackRock employs hundreds of analysts who study market trends, company fundamentals, and economic indicators before investing. Their homework has already been done for you.

🌱

Built For Long-Term Growth

Instead of chasing quick wins, these selections align with BlackRock's philosophy of patient investing for sustainable returns. They're chosen with an eye toward future potential, not just current performance.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions